Loading
A phase 1/2 trial of BVAC-E6E7 (low level) in head and neck squamous cell carcinoma, run by Cellid Co., Ltd., now recruiting.
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. is a phase 1/2 interventional study registered as NCT06797986 by Cellid Co., Ltd., with 37 participants planned, started 2026-02-04 and due to reach its primary completion in 2027-03. Interventions recorded: BVAC-E6E7 (low level), BVAC-E6E7 (high level) and BVAC-E6E7 (RP2D).
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.